首页> 外文期刊>Human vaccines >Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults.
【24h】

Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults.

机译:第一剂和第二剂23价肺炎球菌多糖疫苗接种后十年的抗体持久性,以及第二剂和第三剂对成年人的免疫原性和安全性。

获取原文
获取原文并翻译 | 示例
           

摘要

In a study of older adults, first and second doses of 23-valent pneumococcal polysaccharide vaccine (PN23) induced IgG increases for all 8 vaccine serotypes tested. Participants (N=143, mean age 76 years) were re-enrolled to study antibody levels after ten years, and safety and immunogenicity of another PN23 dose. Ten years after first or second doses, mean IgG concentrations exceeded vaccine-na?ve levels for 7 of 8 serotypes tested. Second and third doses administered at this time were generally well tolerated and were immunogenic, inducing similar postvaccination levels. Immunogenicity is preserved after multiple PN23 doses without evidence of a lower than expected immune response (i.e., without hyporesponsiveness).
机译:在一项针对成年人的研究中,对于所有8种疫苗血清型,第一剂和第二剂23价肺炎球菌多糖疫苗(PN23)诱导的IgG均升高。参加者(N = 143,平均年龄76岁)在10年后重新入组研究抗体水平,以及另一剂PN23的安全性和免疫原性。第一次或第二次给药后十年,平均8种血清型中IgG的IgG浓度超过了疫苗初纯水平。此时给予的第二和第三剂通常耐受性良好,并且具有免疫原性,可诱导相似的疫苗接种后水平。多次PN23剂量后可保持免疫原性,而没有证据表明免疫应答低于预期(即无免疫应答低下)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号